Jayson Bedford
Stock Analyst at Raymond James
(3.94)
# 559
Out of 4,868 analysts
312
Total ratings
56.27%
Success rate
7.4%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $328 → $360 | $301.79 | +19.29% | 27 | May 27, 2025 | |
| ICUI ICU Medical | Maintains: Strong Buy | $197 → $187 | $128.58 | +45.43% | 20 | May 9, 2025 | |
| MASI Masimo | Maintains: Outperform | $204 → $185 | $162.77 | +13.66% | 7 | May 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $119 → $104 | $90.55 | +14.85% | 8 | May 6, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $116 → $108 | $92.95 | +16.19% | 27 | Apr 25, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $122 → $121 | $101.37 | +19.36% | 25 | Apr 24, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $142 | $132.41 | +7.24% | 28 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $162 → $164 | $150.73 | +8.80% | 23 | Apr 16, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $509.49 | +35.04% | 8 | Jan 24, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $81.01 | +22.21% | 30 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $168.59 | +60.15% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $9.29 | +39.94% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $10.22 | -2.15% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $117.72 | +130.21% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.06 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.41 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $73.98 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.80 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $85.73 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.51 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $63.97 | +34.44% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.58 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.91 | - | 3 | Jan 2, 2018 |
Insulet
May 27, 2025
Maintains: Outperform
Price Target: $328 → $360
Current: $301.79
Upside: +19.29%
ICU Medical
May 9, 2025
Maintains: Strong Buy
Price Target: $197 → $187
Current: $128.58
Upside: +45.43%
Masimo
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $162.77
Upside: +13.66%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $119 → $104
Current: $90.55
Upside: +14.85%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $116 → $108
Current: $92.95
Upside: +16.19%
Boston Scientific
Apr 24, 2025
Maintains: Strong Buy
Price Target: $122 → $121
Current: $101.37
Upside: +19.36%
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $132.41
Upside: +7.24%
Johnson & Johnson
Apr 16, 2025
Maintains: Outperform
Price Target: $162 → $164
Current: $150.73
Upside: +8.80%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $509.49
Upside: +35.04%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $81.01
Upside: +22.21%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $168.59
Upside: +60.15%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $9.29
Upside: +39.94%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $10.22
Upside: -2.15%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $117.72
Upside: +130.21%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.06
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $20.41
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $73.98
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $29.80
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $85.73
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.51
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $63.97
Upside: +34.44%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.58
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $11.91
Upside: -